Galderma Group AG 2025 AR2
The report highlights Galderma's strong performance in 2025, achieving record net sales of 5.207 billion USD, representing a 17.7% year-on-year growth on a constant currency basis. The company successfully advanced its ESG strategy, achieving over 98% renewable electricity across all sites and reducing water withdrawal intensity by 15% annually. Galderma also expanded its medical education reach, training and engaging with over 290,000 healthcare professionals. Key product milestones included the successful launch of Nemluvio in the U.S. and the expansion of Relfydess across 17 international markets.
Company: Galderma Group AG
Sector: Health Care
Country: Switzerland
Year: 2025
Type: AR2
Pages: 146
Galderma Group AG
Annual Report
The report highlights Galderma's strong performance in 2025, achieving record net sales of 5.207 billion USD, representing a 17.7% year-on-year growth on a constant currency basis. The company successfully advanced its ESG strategy, achieving over 98% renewable electricity across all sites and reducing water withdrawal intensity by 15% annually. Galderma also expanded its medical education reach, training and engaging with over 290,000 healthcare professionals. Key product milestones included the successful launch of Nemluvio in the U.S. and the expansion of Relfydess across 17 international markets.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women in Management
Workplace Fatalities
Employees